Regarding the growing field of TP53-activating compounds [46] and targeted therapy against TP53 pathway genes [47] (e. g., MDM2), a better characterization of mutational and non-mutational TP53 alterations will become useful in the initial workup of each AML patient [48]. Here, TP53 is linked to acute myeloid leukemia.